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Abstract: The synaptic vesicle protein 2 (SV2) is involved in synaptic vesicle trafficking. The SV2A 
isoform is the most studied and its implication in epilepsy therapy led to the development of the 
first SV2A PET radiotracer [18F]UCB-H. The objective of this study was to evaluate in vivo, using 
microPET in rats, the specificity of [18F]UCB-H for SV2 isoform A in comparison with the other two 
isoforms (B and C) through a blocking assay. Twenty Sprague Dawley rats were pre-treated either 
with the vehicle, or with specific competitors against SV2A (levetiracetam), SV2B (UCB5203) and 
SV2C (UCB0949). The distribution volume (Vt, Logan plot, t* 15 min) was obtained with a 
population-based input function. The Vt analysis for the entire brain showed statistically significant 
differences between the levetiracetam group and the other groups (p < 0.001), but also between the 
vehicle and the SV2B group (p < 0.05). An in-depth Vt analysis conducted for eight relevant brain 
structures confirmed the statistically significant differences between the levetiracetam group and 
the other groups (p < 0.001) and highlighted the superior and the inferior colliculi along with the 
cortex as regions also displaying statistically significant differences between the vehicle and SV2B 
groups (p < 0.05). These results emphasize the in vivo specificity of [18F]UCB-H for SV2A against 
SV2B and SV2C, confirming that [18F]UCB-H is a suitable radiotracer for in vivo imaging of the SV2A 
proteins with PET. 
Keywords: SV2A; SV2B; SV2C; microPET; [18F]UCB-H; epilepsy; PBIF; distribution volume; 
blocking assay; preclinical imaging 
 
1. Introduction 
The synaptic vesicle protein 2 (SV2) is an integral membrane protein with twelve 
transmembrane domains and three N-glycosylation sites in the intravesicular loop. The SV2 protein 
is ubiquitously present in the nerve terminals of the central and peripheral nervous systems, and in 
several types of endocrine cells [1]. This protein is critical for the adequate functioning of the central 
nervous system, acting as a modulator of synaptic transmission [2,3]. Moreover, it has been associated 
with the pathophysiology of epilepsy [4–6]. 
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Previous studies have identified three SV2 isoforms: SV2A, SV2B and SV2C, characterized by 
different expression levels during rodent brain development [7] and adulthood [8]. While the SV2A 
isoform is present across all brain areas, the SV2C isoform can only be found in specific regions, such 
as the striatum, pallidum, midbrain, brainstem, substantia nigra, and the olfactory bulb [9]. The SV2B 
isoform is particularly present in the cerebral cortex, and the cornu ammonis sub-region of the 
hippocampus [10]. The three isoforms present large similarities in their structure: 65% between 
isoforms A and B, 62% between A and C, and 57% between B and C [8]. 
Of these three isoforms, SV2A is the most investigated. The antiepileptic drug levetiracetam 
(Keppra® ) binds to SV2A, suggesting a role for SV2A in the pathology underlying certain forms of 
epilepsy [11–14]. Several studies have shown a correlation between the brain expression of this 
isoform and the clinical efficacy of this drug [5,13]. 
To investigate the role of SV2A in vivo, in 2013 [18F]UCB-H was presented as an imaging agent 
with a nanomolar affinity for human SV2A [3,15–17]. Since then, other PET radiotracers, such as 
[11C]UCB-J, or [11C]UCB-A, have been synthetized to study this protein [3,18–20] (see Figure 1). These 
PET radiotracers appear to be more specific than [18F]UCB-H (pIC50 = 7.8) [3,16], based on their 
respective affinity measured in vitro, with pIC50 = 8.2 for [11C]UCB-J [18] and pIC50 = 7.9 for [11C]UCB-
A [20]. The three radiotracers have demonstrated potential for use as synaptic density biomarkers 
not only in animals, but also in humans [3,21–23]. However, despite the valuable properties of 
[11C]UCB-J and [11C]UCB-A in assessing brain synaptic density in vivo, their clinical application is 
limited to facilities with a cyclotron due to the short half-life of 11C (20.3 min) compared to the half-
life of 18F (110 min). In addition, the use of a PET radiotracer with a longer half-life (such as 18F) allows 
the evaluation of a greater number of patients per day with just one production. Therefore, different 
fluorine-18-labelled derivatives of UCB-J are currently being developed and characterized, such as 
[18F]SDM-8 [24]. The potential of [18F]UCB-H for detecting variations in SV2A has already been 
demonstrated in vivo [25,26]. Nevertheless, as the actual specificity of [18F]UCB-H for SV2A against 
SV2B and SV2C has never been addressed in vivo, we consider that this point deserves more careful 
evaluation. 
 
Figure 1. Chemical structures of [18F]UCB-H, [11C]UCB-J and [11C]UCB-A. 
This paper, therefore, aims to evaluate for the first time the specificity of [18F]UCB-H for the 
SV2A isoform against SV2B and SV2C using microPET imaging in rats, by means of a blocking assay 
between this radiotracer and specific competitors for the three SV2 isoforms. The results will provide 
highly valuable information about the actual potential of [18F]UCB-H as a radiopharmaceutical 
candidate to study the SV2A protein with PET in research or clinical practice. 
2. Results 
Table 1 summarizes the results obtained from the in vitro binding assays. We observe that 
SV2BL presents a high affinity for SV2B (pIC50 = 7.8), but also has an affinity for SV2A similar to 
that of SV2AL (pIC50 = 5.6). 
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Table 1. pIC50 of the competitors used for the different SV2 isoforms. Binding affinities measured for 
human SV2 proteins at 37 °C. Data are presented as mean (n = 3 to 10) from non-linear regression 
analysis of raw data using a sigmoidal dose-response model. Additional data for SV2BL (UCB5203) 
solubility: 0.1 mg/mL, route of administration: ip (suspension in 5% DMSO–1% methyl cellulose in 
water), CEREP @ 10 µM: all targets < 50% inhibition, mouse brain fraction unbound: 37%, mouse brain 
exposure (3 mg/kg, 30–60 min): ~1.8 µM total → 0.66 µM free → ~100 fold IC50 SV2B. Additional data 
for SV2CL (UCB0949) solubility: 0.055 mg/mL, route of administration: ip (suspension in 5% DMSO – 
1% methyl cellulose in water), CEREP @ 10 µM: all targets < 50% inhibition, mouse brain fraction 
unbound: 54%, mouse brain exposure (3 mg/kg, 30–60 min): ~8 µM total → 4.3 µM free → ~270 fold 
IC50 SV2C. 
 Synaptic Vesicle Protein Isoforms 
 SV2A SV2B SV2C 
SV2AL 5.2 -3.1 -3.2 
SV2BL 5.6 7.8 5.5 
SV2CL < 5 5.9 7.8 
In Figure 2, [18F]UCB-H parametric Vt maps are presented for the vehicle group and the three 
pre-treated groups (SV2AL, SV2BL and SV2CL). These pictures highlight a clear reduction of the 
[18F]UCB-H binding throughout the entire brain induced by levetiracetam (SV2AL) pre-treatment at 
10 mg/kg (PET image corresponding to the SV2AL group). 
 
Figure 2. Example of an individual parametric Vt map of [18F]UCB-H binding in rat brain (PET), along 
with the corresponding individual MRI and the overlay of both images (PET + MRI). Rats were pre-
treated 30 min before the 60 min PET acquisition with either vehicle, SV2A competitor (levetiracetam 
[SV2AL] at 10 mg/kg), SV2B competitor (UCB5203 [SV2BL] at 3 mg/kg) and SV2C competitor 
(UCB0949 [SV2CL] at 3 mg/kg). 
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In Figure 3A, we can observe the time activity curves (TACs) corresponding to the four different 
treatments (vehicle, SV2AL, SV2BL and SV2CL), for one of the regions of interest (ROIs): the whole 
brain. The four TACs reveal a high initial uptake of [18F]UCB-H, which peaks around 5 min post-
injection. Subsequently, the radioactivity is quickly washed out of the brain. Some differences can be 
observed in the kinetic of the TAC after pre-treatment with the respective ligands: The highest peak 
activity is observed after pre-treatment with the vehicle and with SV2CL. Interestingly, the pre-
treatments with SV2AL and SV2BL display the same peak of initial uptake. In the case of SV2BL, the 
kinetics of the TAC from 15 to 60 min are similar to the kinetics of the radiotracer after pre-treatment 
with either the vehicle or SV2CL. The TACs for all the ROIs are included in Supplementary Figure S1. 
In addition, the area under each TAC (the AUC) is represented in Figure 3B, where we can observe 
the differences between the [18F]UCB-H uptake after pre-treatment with SV2AL, and after pre-
treatment with the other compounds. 
 
Figure 3. Representative time activity curves (TACs) and AUC (area under each TAC) for the different 
regions of interest (ROIs). (A) TACs extracted from the whole brain as ROI, and normalized by the 
injected activities and the body weight. Lines represent the [18F]UCB-H uptake over a 60 min 
acquisition after pre-treatment with the vehicle, SV2AL, SV2BL, or SV2CL. (B) The bar plots represent 
the AUC in the eight ROIs (mean ± SEM, n = 5). 
Figure 4 presents the mean Vt values for the eight selected brain structures, calculated from the 
previous TACs and the population-based input function (PBIF). Comparing Figures 3B and 4, the 
differences between groups in AUC and in Vt are similar, with the highest value associated to pre-
treatment with the vehicle, and the lowest value for pre-treatment with SV2AL. 
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Figure 4. Vt values for the eight selected brain structures. Bars represent the mean ± SEM (n 
= 5). One-way ANOVA and Scheffe post-hoc tests were performed, with ***p < 0.001 and *p 
< 0.05. 
Table 2 summarizes, for the same regions, the impact on the Vt induced by the blocking 
experiments, expressed as the relative difference in Vt between the vehicle group and the pre-treated 
groups. In the whole brain, mean Vt values of 10.4 ± 0.7, 6.0 ± 0.3, 8.3 ± 0.2 and 9.8 ± 0.3 were obtained 
for the vehicle (control) group, the SV2AL pre-treated group, the SV2BL pre-treated group and the 
SV2CL pre-treated group, respectively. For the eight ROIs, a statistically significant difference was 
observed between the SV2AL pre-treated group and all the other groups (p < 0.001). Furthermore, for 
the whole brain, the cerebral cortex and the inferior and superior colliculus, a statistically significant 
difference was also detected between the vehicle group and the SV2BL pre-treated group (p < 0.05). 
Table 2. Illustration of the impact induced by the blocking experiments, expressed as percentage of 








Whole brain 42.3 19.9 5.6 
Cortex 42.7 21.1 9.1 
Hippocampus 46.8 16.9 2.1 
Inferior colliculus 49.1 23.7 8.5 
Midbrain 46.3 19.1 5.1 
Caudate/Putamen 46.2 20.2 6.2 
Superior colliculus 50.4 23.4 7.6 
Thalamus 45.9 19.7 4.4 
Mean 46.2 20.5 6.1 
SEM 1.0 0.8 0.8 
3. Discussion 
The SV2 protein is critical for the adequate functioning of the central nervous system, acting as 
a modulator of synaptic transmission by priming vesicles in quiescent neurons [4]. The divergent 
roles of the three isoforms which comprise this family have yet to be clarified, although different 
pathologies have been associated with them. As previously stated, the SV2A isoform is associated 
with the physiopathology of epilepsy [5,27]. In contrast, the SV2B isoform is related with prostate 
small cell carcinoma [28] and the SV2C isoform is generally associated with the correct functioning 
of basal ganglia nuclei [9,29,30]. Some studies have evaluated the possible relation between SV2C and 
Parkinson’s disease, as SV2C modulates dopamine release [29,31]. 
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This paper’s goal was to evaluate, for the first time, in vivo the specificity of the [18F]UCB-H 
radiotracer in targeting the SV2A isoform compared to SV2B and SV2C. The relevance of such a study 
stems from the fact that in vivo SV2A quantification can be considered to be an indirect measure of 
the synaptic density [2,3,18], which is a key parameter for fundamental research and for the clinic. 
Before discussing the results obtained during these blocking experiments, we have to address 
some general considerations. Firstly, the results presented issue from the microPET imaging 
technique. Like many other microPET cameras, the Focus120 used during this work has a spatial 
resolution of 1.5 mm, at best hampering the study of brain structures of small size due to the partial 
volume effect [32,33]. Secondly, the rat brain distributions of the three SV2 protein isoforms [7–9] 
indicate that almost all major brain structures express at least two SV2 protein isoforms. SV2A, the 
most extensively studied, is ubiquitously distributed [1,8]. Like SV2A, SV2B can be found in almost 
all the rat brain structures with few subtle differential expressions in some hippocampal 
substructures like CA3 and the dentate gyrus, along with the reticular nucleus of the thalamus and 
some small areas in the brain stem [8,9,34]. Unfortunately, these regions are far too small to be 
correctly quantified with microPET. Janz and Sudhof showed that unlike SV2A and SV2B, the SV2C 
protein is characterized by much more restricted localization in brain regions considered to be 
evolutionarily well preserved in rats: The olfactory bulb, the striatum, the substantia nigra, and some 
nuclei in the pons and the medulla oblongata [9]. As we can see, it is impossible to find well defined 
brain structures for in vivo microPET quantification in which one of the three isoforms is uniquely or 
even mostly expressed. Another important point is that we do not have a clear picture of the 
respective proportions of each isoform present in the main rat brain structures. All these 
considerations will have to be taken into account in the following discussion. Accordingly, we have 
decided to select eight major ROIs to ensure robust in vivo quantification with microPET: Whole 
brain, cortex, hippocampus, inferior colliculus, superior colliculus, midbrain, caudate putamen and 
thalamus. 
The [18F]UCB-H Vt values obtained during this study for the vehicle pre-treated group, 
calculated using the PBIF [35] were in good agreement with those previously published for rats 
[35,36]. This is important in order to establish the consistency of the proposed methodology. The 
blocking experiments realized with SV2AL at 10 mg/kg demonstrated a clear significant competition 
(46.2%) between levetiracetam and [18F]UCB-H in eight selected ROIs. These values are of the same 
order of magnitude as those previously reported in rats [36]. According to the potency of 
levetiracetam for SV2A against SV2B and SV2C (Table 2), we can conclude that SV2A is one of the 
main target of [18F]UCB-H in vivo in rats. 
After performing a blocking experiment with SV2CL at 3 mg/kg, we obtained TACs with similar 
peaks and kinetics to the TAC corresponding to pre-treatment with the vehicle, in all ROIs. The 
quantification of the radiotracer uptake, using the Vt, highlighted no statistically significant in vivo 
competition between SV2CL and [18F]UCB-H in any of the eight selected ROIs. From this we can infer 
that SV2CL pre-treatment has either no impact or an impact of very small size. The population used 
(n = 5) is not sufficient to demonstrate an effect of small size (f = 0.10), but is optimal to detect medium 
(f = 0.25) and large effect sizes (f = 0.5). Another important point is that a highly potent SV2C 
competitor like UCB0949 (pIC50 of 7.8) was unable to modify [18F]UCB-H binding in brain structures 
with a high expression of SV2C, like the midbrain or the caudate/putamen [9]. The reduction 
measured in these regions was of the same order of magnitude as that found in the other structures. 
These considerations support the theory that SV2C does not seem to be the main target of [18F]UCB-
H in rats. 
The pre-treatment with SV2BL at 3 mg/kg resulted in a TAC with a peak as high as that obtained 
after pre-treatment with SV2AL. However, it features kinetics which are similar to those obtained 
after pre-treatment with the vehicle or SV2CL. This lower peak could be attributed to an initial non-
specific binding of SV2BL to the SV2A protein, for which it presents an affinity which is similar to that 
of SV2AL, with a pIC50 = 5.6. After the peak, the SV2BL TAC follows a similar shape and level to those 
of pre-treatment with the vehicle and SV2CL, indicating a washing out effect of this fraction of non-
specific binding of SV2BL to the SV2A protein. In order to confirm this hypothesis, a similar 
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experiment with a SV2BL with a lower affinity for SV2A should be performed. However, the SV2BL 
used in this paper is currently the only one available. In addition to the previous analysis, we 
evaluated the changes in Vt after pre-treatment with SV2BL. In these results, we can observe a 
consistent mean reduction of 20.5% of the Vt values in the eight selected ROIs. The SV2BL is 
characterized by a pIC50 of 7.8 for the SV2B isoform. Such a highly potent competitor is expected to 
effectively impede the binding of any radioligand to the SV2B isoform. If SV2B was the main target 
for [18F]UCB-H, the blocking induced with this highly efficient SV2BL would have been very 
pronounced and much higher than the 20% measured. In order to explain the 20% reduction of 
[18F]UCB-H Vt values, we have to take into account that SV2BL also presents some potency for SV2A. 
SV2BL has a pIC50 of 5.6, which is of the same order of magnitude as that of levetiracetam. Thus, the 
SV2BL ligand has some affinity for SV2A, which could lead to partial blocking of SV2A. Hence, the 
20% reduction observed is most likely linked to SV2A blocking induced by SV2BL. Accordingly, we 
can conclude that SV2B does not seem to be the main target of [18F]UCB-H in vivo in rats. 
We are aware that the respective affinities of SV2BL and SV2CL are a problem for the 
interpretation of the data, but we have to consider that today UCB5203 and UCB0949 are the only 
compounds that can be used for this purpose. 
4. Materials and Methods 
4.1. Animals 
Twenty male Sprague Dawley CD rats (five weeks old) were used, bred by Janvier Laboratories 
(France). The animals were housed in pairs for three weeks under standard 12:12 h light/dark 
conditions, maintaining room temperature at 22 °C, and humidity at approximately 50%. Standard 
pellet food and water were provided ad libitum. 
The experimental procedures and protocols used in this investigation (“Synap-SV2A project” 
files 14-1753 and 13-1573) were reviewed and approved by the Institutional Animal Care and Use 
Committee of the University of Liege, according to the Helsinki declaration, and conducted in 
accordance with the European guidelines for care of laboratory animals (2010/63/EU). Moreover, the 
Animal Research Reporting In Vivo Experiments (ARRIVE) guidelines [37] were followed as closely 
as possible to confer a minimal intrinsic quality to the study. 
4.2. Radiopharmaceutical Production and Drugs 
[18F]UCB-H was produced through one-step radiolabeling of a pyridyliodonium precursor. This 
method provides 34% ± 2% of injectable [18F]UCB-H (uncorrected radiochemical yield) from up to 
285 GBq (7.7 Ci) of [18F]fluoride (specific activity of 815 ± 185 GBq/μmol and measured purity of 99.8 
± 0.5 wt %); this has previously been reported in Warnier et al. [17]. 
The ligand for the SV2A isoform (SV2AL) was purchased as an injectable solution (levetiracetam, 
Keppra® , UCB Pharma S.A. Brussels, Belgium). At the present time, there are no commercially 
available specific ligands for the other two SV2 isoforms (SV2B and SV2C). The competitors used 
were obtained from UCB Pharma s.a.: UCB5203 for SV2B (SV2BL, MW: 236.238g/mol) and UCB0949 
for the SV2C (SV2CL, MW: 281.197g/mol). The information on these compounds was supplied by 
UCB Pharma s.a. The respective affinities for the different SV2 isoforms are presented in Table 2. 
The competitors were prepared daily in a vehicle composed of distilled water containing 1% 
methyl cellulose (viscosity: 15 cP, Sigma-Aldrich, Overijse, Belgium) and 5% dimethyl sulphoxide 
(DMSO, Sigma-Aldrich, Belgium). The concentrations differed depending on the product 
specifications and their respective pharmacokinetics, provided by UCB Pharma s.a. The dosing used 
was 10 mg/kg for SV2AL, 3 mg/kg for SV2BL, and 3 mg/kg for SV2CL. All solutions were administered 
through the intraperitoneal (i.p.) route in a total volume of 1 mL per kg of body weight. The animals 
used as a control group (vehicle) received an equal volume of vehicle through the same route of 
administration. 
4.3. In Vitro Binding Assays 
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Reagents and reference compounds used were of analytical grade and obtained from various 
commercial sources. All cell culture reagents were obtained from Invitrogen (Merelbeke, Belgium). 
Radioligands (3H-UCB30889, 1184 GBq/mmol; 3H-UCB1418435, 925 GBq/mmol; and 3H-UCB101275-
1, 1110–1480 GBq/mmol) were obtained from G.E Healthcare, Amersham, UK (now Perkin Elmer, 
Zaventem, Belgium) and reference compounds (levetiracetam, UCB108649-1 and UCB101275-1) were 
custom synthesized and stored according to manufacturer’s recommendations. Test and reference 
compounds were dissolved in 100% DMSO or H2O to give 1 or 10 mM stock solution. The final DMSO 
concentration in assays was 0.1% unless otherwise stated. 
Cell lines generated at UCB Biopharma were human embryonic kidney (HEK) 293 cells expressing 
human SV2A, SV2B or SV2C proteins. Cells were cultured in Dulbecco’s Modified Eagle medium. The 
culture medium was supplemented with foetal bovine serum (FBS, 10%), 2 mM L-glutamine, 50 to 100 
U/mL penicillin, 50 to 100 µg/mL streptomycin, and 200 µg/mL hygromycin B. Cells were grown at 37 
°C with 95% air. Confluent cells were detached by 10 min incubation at 37 °C in phosphate buffered 
saline (PBS) containing 0.02% EDTA. Culture flasks were washed with 15 mL of ice-cold PBS. The cell 
suspension was centrifuged at 1500× g for 10 min at 4 °C. The pellet was homogenized in 15 mM Tris-
HCl buffer (pH 7.5) containing 2 mM MgCl2, 0.3 mM EDTA, and 1 mM EGTA (buffer A) using a 
glass/teflon homogenizer. The crude homogenate was subjected to a freeze and thaw cycle in liquid 
nitrogen and DNAse (1 µL/mL) was then added. The homogenate was further incubated for 10 min at 
25 °C before being centrifuged at 40,000× g for 25 min at 4 °C. The pellet was re-suspended in buffer A 
and washed once under the same conditions. The final crude membrane pellet was re-suspended at a 
protein concentration of 1–3 mg/mL in 7.5 mM Tris-HCl buffer (pH 7.5 at 25 °C) containing 250 mM 
sucrose and stored in liquid nitrogen until use. 
Membranes were incubated in binding buffer (see Table 3) containing test compound or positive 
control in the presence of the radioligand. The non-specific binding (NSB) was defined as the residual 
binding observed in the presence of a high concentration (1000 fold its Ki) of a specific unlabeled 
reference compound. Membrane-bound and free radioligands were separated by rapid filtration 
through glass fiber filters (GF/C). Samples and filters were rinsed using at least 6 mL of washing buffer. 
The entire filtration procedure did not exceed 10 s per sample. The radioactivity trapped on the filters 
was counted by liquid scintillation in a β-counter. To determine the affinity of a compound for a given 
target, competition curves were performed with at least 10 concentrations of compound spanning at 
least 5 log units. 
Table 3. Details of the in vitro binding assay determination. Percentage of inhibition was calculated 
as follows: % INHIBITION = 100 − [((BI − NSB)/(B0 − NSB)) × 100], where B0 and BI represent the 
binding observed in the absence and presence of the test compound, respectively (dpm), NSB is the 
radioligand non-specific binding (dpm). Raw data were analyzed by non-linear regression using 
XLfitTM (IDBS, London, Great Britain) according to the following generic equation: B = NSB + [(B0 − 
NSB)/(1 + (((10X)/(10−pIC50))nH))], where B is the radioligand bound in the presence of the unlabeled 
compound (dpm), NSB is the radioligand non-specific binding (dpm), B0 is the radioligand bound in 
the absence of unlabeled compound (dpm), X is the concentration of unlabeled compound (log M), 
pIC50 is the concentration of unlabeled compound that inhibits the radioligand specific binding by 
50% (−log M), and nH is the Hill coefficient. 
In Vitro 
Binding Details 
hSV2A Assay hSV2B hSV2C 
Binding buffer 50 mM Tris-HCl (pH7.4) containing 2 mM MgCl2 
Filtration buffer Ice-cold 50 mM Tris-HCl (pH 7.4) 
Incubation time 120 min at 37 °C in 0.5 mL 120 min at 37 °C in 0.5 mL 120 min at 37 °C in 0.2 mL 
Radioligand 3H-UCB30889 (4 nM) 3H-UCB1418435 (8 nM) 3H-UCB101275-1 (20 nM) 
















4.4. PET Acquisitions 
The animals (n = 5 per group) were anesthetized using 4% isoflurane in air at a flow rate of 1 
L/min during induction and 1.5% to 2% isoflurane in air at 0.6 L/min during maintenance. Respiration 
rate and rectal temperature were continuously measured using a physiological monitoring system 
(Minerve, France). The temperature was maintained at 37 ± 0.5 °C using an air warming system. 
MicroPET scans were performed with a Siemens FOCUS 120 microPET (Siemens, Knoxville, TN, 
USA). The animals were anesthetized and pre-treated i.p. with vehicle, SV2AL, SV2BL, or SV2CL. 
Thirty minutes later, they were installed in the microPET scanner and [18F]UCB-H was injected via 
the lateral tail vein (44.7 ± 3 MBq, 0.55 mL), simultaneously starting a 60 min emission scan, in list 
mode. Finally, a 10 min transmission scan was performed in a single event acquisition mode, using a 
57Co source. The acquired data were then reframed as follows: 6 × 5 s, 6 × 10 s, 3 × 20 s, 5 × 30 s, 5 × 60 
s, 8 × 150 s, and 6 × 300 s. For each frame, a total of 95 trans-axial slices were obtained using Fourier 
rebining (FORE), followed by 2D ramp filtered backprojection (FBP), in 256 × 256 matrix. The slice 
thickness was 0.796 mm and the in-slice pixel size was 0.433 mm. 
Immediately after the PET acquisition, the anesthetized rats were transferred into a 9.4 Tesla 
MRI horizontal bore system (Agilent Technologies, Palo Alto, CA, USA), with a 72 mm inner 
diameter volumetric coil (Rapid Biomedical GmbH, Würzurg, Germany). Anatomical T2-weighted 
brain images were obtained using a fast spin echo multi-slice sequence with the following 
parameters: TR = 2000 ms, TE = 40 ms, matrix = 256 × 256, FOV = 45 × 45 mm, 30 contiguous slices of 
thickness = 0.80 mm and in-plane voxel size = 0.176 × 0.176 mm. 
4.5. Imaging Data Processing 
PMOD software (Version 3.6, PMOD Technologies, Zurich, Switzerland) was used to process 
the imaging data. The structural MRI images were firstly co-registered to the corresponding PET 
images, and subsequently spatially normalized into the PMOD MRI T2 template. Finally, the inverse 
normalization parameters were calculated and applied to the PMOD rat brain atlas to bring it in the 
individual PET space. From this atlas, eight relevant regions of interest (ROIs) were chosen according 
to their differential expression of SV2A, SV2B and SV2C: whole brain, cortex, caudate/putamen, 
hippocampus, inferior colliculus, superior colliculus, midbrain and thalamus. 
Individual time-activity curves (TACs) were extracted for each ROIs and normalized by the 
body weight and the injected dose of radiotracer to be expressed as standardized uptake value (SUV). 
A population-based input function (PBIF) published by our laboratory [35] was used to avoid arterial 
blood sampling during the acquisitions. The distribution volume (Vt), was determined by Logan plot 
kinetic modelling using the TACs and the PBIF. The equilibration time (t*) was fixed at 15 min 
(starting point of the range used in the multi-linear regression analysis). 
4.6. Statistical Analysis 
The results are presented as mean (Vt) ± standard error of the mean (SEM). All the data were 
tested for normal distribution with Levene’s test for homogeneity, and with a Kolmogorov–Smirnov 
test for normality. Data were analyzed using one-way analysis of variance (ANOVA) followed by 
Scheffe post-hoc tests. 
All statistical analyses were performed with the statistics software Statistica 12 (Statsoft, France) 
and GraphPad Prism (version 6, GraphPad software, Inc., San Diego, CA, USA). The critical level of 
statistical significance was always set at p < 0.05. 
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5. Conclusions 
For the first time, the specificity of a radiopharmaceutical compound for the three SV2 protein 
isoforms was assessed in vivo, in rats. The results obtained clearly indicated that SV2A was the main 
target of [18F]UCB-H, and confirmed that [18F]UCB-H is a suitable radiotracer for in vivo imaging of 
the SV2A proteins with PET. Consequently, [18F]UCB-H is an interesting candidate to study SV2A-
associated pathologies. 
Supplementary Materials: The following are available online. Figure S1: TACs extracted from the eight ROIs, 
and normalized by the injected activities and the body weight. Lines represent the [18F]UCB-H uptake over a 60 
min acquisition after pre-treatment with the vehicle, SV2AL, SV2BL, or SV2CL (mean ± SEM; n = 5). 
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analysis, M.E.S., G.B., M.A.B., A.S. and A.P.; investigation, M.E.S. and G.B.; resources, N.M., J.M., F.M., F.G., C.L. 
and A.L.; data curation, M.A.B.; writing—original draft preparation, M.E.S.; writing—review and editing, G.B., 
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